Table 2.

Coexistent genetic alterations including EGFR, ROS1, and EML4-ALK in MPA and LA cases

Variables	MPA(n = 55)	LA(n = 76)	p
Single alteration			0.028*
EGFR +	40(72.7%)	41(53.9%)
ROS1 +	2(3.6%)	0
EML4-ALK+	1(1.8%)	1(1.3%)
Double alteration			0.043*
EGFR+; ROS1+	2(3.6%)	1(1.3%)
ROS1+; EML4-ALK+	2(3.6%)	0
No alteration			0.001**
EGFR-; ROS1-; EML4-ALK-	8(14.5%)	33(43.5%)

MPA micropapillary lung adenocarcinoma, LA lung adenocarcinoma without micropapillary component, EGFR+ EGFR mutation, EGFR- EGFR wild type, ROS1+ ROS1 fusion, ROS1- no ROS1 fusion, EML4-ALK+ EML4-ALK fusion, EML4-ALK- no EML4-ALK fusion

*p<0.05; **p<0.01 compared with LA